Investigational drug · Phase 2
lonigutamab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Thyroid Eye Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 1, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "lonigutamab"
First trial start
2023
Feb 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "lonigutamab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Thyroid Eye Disease
Approved drugs for the same conditions: Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "lonigutamab" as an intervention, largest first.
ACELYRIN Inc.Industry
NCT05683496 · 31 participants · Start Feb 14, 2023 · Primary completion May 26, 2025
Drug: lonigutamab; Placebo · For: Thyroid Eye Disease
Sites: Jacksonville, Florida; Atlanta, Georgia; Ann Arbor, Michigan · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Lonigutamab Inhibits Hyaluronan Production by Reducing IGF-1R Levels in Thyroid Eye Disease Orbital Fibroblasts.
Roztocil E, Husain F, Patrick CC, et al. · J Clin Endocrinol Metab 2026
- Emerging therapies in the medical management of thyroid eye disease.
Kamboj A, Harrison AR, Mokhtarzadeh A · Front Ophthalmol (Lausanne) 2023
Also in development for Thyroid Eye Disease
- VRDN-003ZL-1109Phase 35 trials
Viridian Therapeutics, Inc. · Thyroid Eye Disease, Thyroid Eye Disease (TED)
- BatoclimabIMVT-1401Phase 33 trials
Immunovant Sciences GmbH · Thyroid Eye Disease, Graves Disease
- IBI311Phase 33 trials
Innovent Biologics (Suzhou) Co. Ltd. · Thyroid Eye Disease, Thyroid Eye Disease, TED
- PacibekitugTOUR006, PAC001Phase 33 trials
Tourmaline Bio, Inc., a Novartis Company · Myocardial Infarction, Thyroid Eye Disease, Chronic Kidney Diseases
- KHN939Phase 32 trials
Beijing Kanghong Biological Medicine Co., Ltd. · Thyroid Eye Disease
- linsitinibPhase 32 trials
Sling Therapeutics, Inc. · Graves Orbitopathy, Thyroid Eye Disease, TED, Thyroid Eye Disease
- AMG 732Phase 22 trials
Amgen · Thyroid Eye Disease
- LASN01Phase 22 trials
Lassen Therapeutics 1 PTY LTD · Thyroid Eye Disease, Pulmonary Fibrosis, Graves Ophthalmopathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.